【摘要】 给家兔单次iv或ig Na₂SeO₃ 2.0mg/kg,iv血药-时曲线符合线性三室开放模型,药代动力学参数为t_3/2a 0.16±0.08d,t_1/2β9.93±2.52d,t_1/2π0.13±0.08 h,ig血药-时曲线符合二室开放模型,药代动力学参数t_1/2（Ka）2.69±0.56h,t_1/2a 0.96±0.45d,t_1/2 β9.31±3.36 d。多次给硒时,每7d,14d igNa₂SeO₃ 2.0mg/kg,每10d iv Na₂SeO₃ 1.5mg/kg各组达到90％以上稳态血药水平的时间分别为35d,45d和30d。更多还原

【Abstract】 Sodium selenite has been used for the prevention of keshan disease and employed in the treatment of Kaschin-Beck’s disease. The rational design of safe and efficacious dosage regimens of sodium selenite have not been yet clear. Therefore the pharmacokinetics of sodium selenite in rabbits was studied and discussed in this paper. A single iv or ig of sodium selenite 2.0 mg/kg were given to 10 male rabbits. The multiple doses of sodium selenite 2.0 or 1.5 mg/kg were administered in 16 male rabbits. Selenium in whole blood was determined fluorophotomerically. The concentration-time curve following a single iv of sodium selenite in rabbits was found to be of 3-compartment open model. The pharmacokineticparameters were x±SD:t(1/2)α0.16± 0.08 d, t(1/2)β 9.93±2.52 d, t(1/2)π 0.13±0.08 h. The concentration-time curve following a single ig of sodium selenite showed a pattern of 2-compartment open model. The pharmacokinetic parameters were:t(1/2) (Ka) 2.69±0.56 h, t(1/2) 0.96± 0.45 d, t(1/2)β 9.31±3.36 d. Sodium selenite was given orally 2 mg/kg every 7 d, or every 14 d, more than 90 % of steady-state levels reached within 35 d, or by 45 d, respectively. When it was given intravenously 1.5 mg/kg every 10d, more than 90 % of steady-state levels reached by 30 d.更多还原